When medical care id delivered where they feel their best.
Once you've selected an opportunity, you will be asked to register before you can apply for the position. Please write down your username and password since you will need this information to check on your application status and to submit an application for future positions. You can apply for up to two positions at a time. You cannot apply for another position until one of your two applications has been released.
Before applying for a position, be sure to allot enough time to complete the application process and assessment.
Before submitting your application, check that you have filled out the entire application. If any portion of the application is left blank, especially the education and job history sections, then you may not be considered for the position. Also, ensure that the shift and work hours you list in your application match the hours and shift listed for the position. You will also want to take the assessment at the end of the application. If you experience computer issues getting to the assessment, the recruiter can send you a new link, at a later time.
Your application will be retained in our da tabase, but you will not automatically be considered for other positions in the future. Job Agents are an excellent way to be notified when new positions are posted. Click on the "Log in Now" and follow the instructions to create your own Job Agent.
Please submit an internal application transfer using the link for current employees. Remember to speak with your manager before applying for a transfer. If you have a resume, attach it to the bottom of the transfer application. You must be in your current position for six months before you can apply for a transfer.
Cook Children's Talent Acquisition team has put together some tips and tricks to help you stand ou
Once you've selected an opportunity, you will be asked to register before you can apply for the position. Please write down your username and password since you will need this information to check on your application status and to submit an application for future positions. You can apply for up to two positions at a time. You cannot apply for another position until one of your two applications has been released.
Before applying for a position, be sure to allot enough time to complete the application process and assessment.
Before submitting your application, check that you have filled out the entire application. If any portion of the application is left blank, especially the education and job history sections, then you may not be considered for the position. Also, ensure that the shift and work hours you list in your application match the hours and shift listed for the position. You will also want to take the assessment at the end of the application. If you experience computer issues getting to the assessment, the recruiter can send you a new link, at a later time.
Your application will be retained in our database, but you will not automatically be considered for other positions in the future. Job Agents are an excellent way to be notified when new positions are posted. Click on the "Log in Now" and follow the instructions to create your own Job Agent.
Please submit an internal application transfer using the link for current employees. Remember to speak with your manager before applying for a transfer. If you have a resume, attach it to the bottom of the transfer application. You must be in your current position for six months before you can apply for a transfer.
Cook Children's Talent Acquisition team has put together some tips and tricks to help you stand ou
Nulla rhoncus eros id tellus luctus, nec commodo tortor semper. Vivamus eget turpis vitae mi varius interdum.
Quisque convallis lacus ac tellus egestas, et auctor enim aliquam.
Curabitur eu dui ut diam luctus sollicitudin at sed lorem. Aliquam pharetra felis eget lacus egestas, non elementum risus consequat.
Once you've selected an opportunity, you will be asked to register before you can apply for the position. Please write down your username and password since you will need this information to check on your application status and to submit an application for future positions. You can apply for up to two positions at a time. You cannot apply for another position until one of your two applications has been released.
Before applying for a position, be sure to allot enough time to complete the application process and assessment.
Before submitting your application, check that you have filled out the entire application. If any portion of the application is left blank, especially the education and job history sections, then you may not be considered for the position. Also, ensure that the shift and work hours you list in your application match the hours and shift listed for the position. You will also want to take the assessment at the end of the application. If you experience computer issues getting to the assessment, the recruiter can send you a new link, at a later time.
Your application will be retained in our database, but you will not automatically be considered for other positions in the future. Job Agents are an excellent way to be notified when new positions are posted. Click on the "Log in Now" and follow the instructions to create your own Job Agent.
Please submit an internal application transfer using the link for current employees. Remember to speak with your manager before applying for a transfer. If you have a resume, attach it to the bottom of the transfer application. You must be in your current position for six months before you can apply for a transfer.
Cook Children's Talent Acquisition team has put together some tips and tricks to help you stand out.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque eu urna vitae massa sodales porttitor.
Curabitur cursus commodo est, id dapibus neque congue id. Cras sed consequat dolor.
Proin dignissim nibh nulla, et congue ipsum mattis et. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia curae; Quisque consectetur, felis vitae dictum pellentesque, lectus turpis interdum leo, eu eleifend mi eros in orci. Etiam nec maximus erat. Morbi fermentum sapien vel velit tincidunt tristique. Nam vitae nisi risus. Duis molestie blandit rhoncus. Maecenas feugiat ipsum vitae vehicula tincidunt. Cras feugiat facilisis accumsan. Curabitur aliquam ut leo id bibendum. Integer vitae enim imperdiet, laoreet elit sed, fermentum orci. Curabitur viverra ut diam ut maximus. Morbi pharetra interdum elit vitae placerat. Donec posuere elementum sapien sed elementum. Nulla porta consectetur euismod. Duis ultrices purus nisi, vitae consectetur ligula iaculis eu.
Nulla rhoncus eros id tellus luctus, nec commodo tortor semper. Vivamus eget turpis vitae mi varius interdum. Quisque convallis lacus ac tellus egestas, et auctor enim aliquam. Curabitur eu dui ut diam luctus sollicitudin at sed lorem. Aliquam pharetra felis eget lacus egestas, non elementum risus consequat. Donec tincidunt auctor bibendum. Phasellus laoreet diam at erat blandit, non consequat enim commodo. Nam vel ante facilisis, commodo eros nec, fermentum tortor. Suspendisse sit amet sem non leo volutpat elementum. Nulla dapibus libero dui, sed dignissim augue dignissim eu.
YouTube Caption text Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Phasellus in pretium odio, eu fringilla justo
Loading primary care locations...
Cras pharetra sollicitudin libero, ac sagittis erat egestas lacinia. Etiam porttitor tincidunt odio, eu consectetur sem consequat eu. Fusce a facilisis est, eget semper eros. Vestibulum auctor interdum sem. Sed sodales id turpis sed vulputate. Aliquam erat volutpat. Nam faucibus aliquam lobortis. In nec purus dolor.
here is some text to test out this field for testing
YouTube Caption text Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.
A 2-part Phase 2 Study of Safety, Pharmacokinetics and Biomarkers in Children with Duchenne Muscular Dystrophy including a Randomized, Double-Blind, Placebo-Controlled Part A, Followed by an Open-Label Part B
Primary Investigator: Marks MD, Warren
IRB ID: 2023-003 (OPEN)
A Long-term Multicenter Prospective Observational Study Evaluating the Comparative Effectiveness and Safety of Sarepta Gene Transfer Therapy vs. Standard of Care in Participants with Duchenne Muscular Dystrophy under Conditions of Routine Clinical Practice (BEYOND)
Primary Investigator: Marks MD, Warren
IRB ID: 2023-084 (OPEN)
A Long-term, Open-label Extension (OLE) Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
Primary Investigator: Roy, Sani
IRB ID: 2023-068 (OPEN)
A Master Protocol For A Phase 3, Multicenter, Open-Label, Long-Term Extension Study To Evaluate The Long-Term Efficacy And Safety Of Mirikizumab In Children And Adolescents With Moderate-To-Severe Ulcerative Colitis Or Crohn’S Disease
Primary Investigator: Huang, MD, Clifton
IRB ID: 2021-008 (OPEN)
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications
Primary Investigator: Eames MD, Gretchen
IRB ID: 2023-095 (OPEN)
A Multicenter Multinational Observational Study of Children with Hypochondroplasia
Primary Investigator: Steelman MD, Joel
IRB ID: 2024-023 (OPEN)
A multicenter safety study of unlicensed, investigational, cryopreserved cord blood units (CBUs) manufactured by the National Cord Blood Program (“NCBP”) and provided for unrelated hematopoietic stem cell transplantation of pediatric and adult patients
Primary Investigator: Eames MD, Gretchen
IRB ID: 2015-077 (OPEN)
A Multimodal Biomarker-based Predictive Model for Infantile Spasm
Primary Investigator: Keator MD, Cynthia
IRB ID: 2022-006 (OPEN)
A Phase 1/2 Trial of CBL0137 (NSC# 825802, IND# 155843) in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma
Primary Investigator: Zhao, MD, Sibo
IRB ID: 2022-024 (OPEN)
A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG) - ACNS1821
Primary Investigator: Zhao, MD, Sibo
IRB ID: 2022-054 (OPEN)
A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC# 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/=1 to <31 Years Old with First Relapse
Primary Investigator: Heym MD, Kenneth
IRB ID: 2021-006 (OPEN)
A Phase 2 Study of DS-8201a (NSC#807708, IND#153036) in Adolescents, or Young Adults with Recurrent HER2+ Osteosarcoma
Primary Investigator: Granger MD, Meaghan
IRB ID: 2021-086 (TEMPORARILY CLOSED TO ACCRUAL)
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND# 133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
Primary Investigator: Heym MD, Kenneth
IRB ID: 2017-049 (OPEN)
A Phase 2 study of SNDX-5613 in combination with chemotherapy for patients with relapsed or refractory KMT2A-rearranged infant leukemia
Primary Investigator: Pacenta, Holly
IRB ID: 2024-114 (OPEN)
A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor
Primary Investigator: Zhao, MD, Sibo
IRB ID: 2021-071 (OPEN)
A Phase 2, Randomized, Controlled, Multicenter Study of Vosoritide in Children With Idiopathic Short Stature
Primary Investigator: Steelman MD, Joel
IRB ID: 2024-116 (OPEN)
A PHASE 2, TWO-STAGE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF RLS-0071 IN NEWBORNS WITH MODERATE OR SEVERE HYPOXIC-ISCHEMIC ENCEPHALOPATHY UNDERGOING THERAPEUTIC HYPOTHERMIA WITH LONG-TERM FOLLOW-UP (STAR)
Primary Investigator: Riley MD, David
IRB ID: Premier_RLS-0071-202 (ReAlta)_Riley (OPEN)
A Phase 3 Multicentered Randomize Platform Study OFP19 Inhibition of the IL-23 Pathway to establish efficacy in pediatric Crohn's Disease
Primary Investigator: Huang, MD, Clifton
IRB ID: 2024-064 (OPEN)
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma
Primary Investigator: Albritton MD, Karen
IRB ID: 2022-122 (OPEN)
A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations
Primary Investigator: Heym MD, Kenneth
IRB ID: 2020-072 (OPEN)
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Primary Investigator: Heym MD, Kenneth
IRB ID: 2020-022 (OPEN)
A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma
Primary Investigator: Greer MD, Chelsee
IRB ID: 2024-050 (OPEN)
A Phase 3 Study of Selumetinib or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations - ACNS1931
Primary Investigator: Zhao, MD, Sibo
IRB ID: 2021-017 (TEMPORARILY CLOSED TO ACCRUAL)
A Phase 3, Multicenter, Randomized, Platform Study of p19 Inhibition of the IL-23 Pathway to Establish Efficacy in Pediatric Crohn’s Disease. A Phase 3, Multicenter, Randomized Clinical Study to Evaluate Mirikizumab in Pediatric Crohn’s Disease.
Primary Investigator: Huang, MD, Clifton
IRB ID: 2024-065 (OPEN)
A Phase 3, Multicenter, Randomized, Platform Study of p19 Inhibition of the IL-23 Pathway to Establish Efficacy in Pediatric Crohn’s Disease MACARONI-23
Primary Investigator: Huang, MD, Clifton
IRB ID: 2024-063 (OPEN)
A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis (VX20-121-104)
Primary Investigator: Pancham MD, Krishna
IRB ID: 2022-056 (OPEN)
A Phase 3, open-label, single-arm, repeated-dose study to evaluate the safety and tolerability, pharmacokinetics, and antiviral activity of Maribavir for the treatment of cytomegalovirus (CMV) infection in children and adolescents who have received a hematopoietic stem cell transplant (HSCT) or a solid organ transplant (SOT).
Primary Investigator: Howrey MD, Richard P.
IRB ID: 2022-044 (OPEN)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Participants with Congenital or Acquired Primary Autoimmune or Idiopathic Chronic Neutropenic Disorders who are experiencing recurrent and/or serious infections.
Primary Investigator: Beam MD, Donald
IRB ID: 2024-091 (OPEN)
A phenomenological study of Cultural Humility in Patient and Physician Encounters
Primary Investigator: Campbell, Throy
IRB ID: 2023-081 (OPEN)
A Process Improvement Tool to Enhance and Monitor the Treatment of Children and Adolescents with Diabetic Ketoacidosis (DKA)
Primary Investigator: Wilson MD, Don
IRB ID: 2013-045 (OPEN)
A Prospective, Long Term Registry of Patients with a Diagnosis of Spinal Muscular Atrophy
Primary Investigator: Acord, Stephanie
IRB ID: 2019-052 (OPEN)
A Randomised Phase 3 trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumours
Primary Investigator: Vallance MD, Kelly
IRB ID: 2018-089 (OPEN)
A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS)
Primary Investigator: Vallance MD, Kelly
IRB ID: 2021-083 (TEMPORARILY CLOSED TO ACCRUAL)
A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy
Primary Investigator: Albritton MD, Karen
IRB ID: 2023-096 (OPEN)
A randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of ABX464 once daily for induction treatment in subjects with moderately to severely active ulcerative colitis
Primary Investigator: Huang, MD, Clifton
IRB ID: 2022-092 (OPEN)
A randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of ABX464 once daily for maintenance treatment in patient with moderate to severely active ulcerative Colitis
Primary Investigator: Huang, MD, Clifton
IRB ID: 2022-103 (OPEN)
A REsearch Study to Advance the CF THerapeutics Pipeline for People without Modulators (REACH)
Primary Investigator: Schultz MD, Karen D
IRB ID: 2024-070 (OPEN)
A retrospective cohort study of response and survival in pediatric patients with relapsed and refractory acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LLy) treated with contemporary salvage therapy
Primary Investigator: Heym MD, Kenneth
IRB ID: 2021-016 (OPEN)
A Retrospective Evaluation of High-Flow Intracranial Arteriovenous Malformations in Neonates: Clinical Management and Outcomes in North America
Primary Investigator: Riley MD, David
IRB ID: 2024-052 (OPEN)
A RETROSPECTIVE STUDY OF INOTUZUMAB OZOGAMICIN IN PATIENTS WITH DOWN SYNDROME AND ACUTE LYMPHOBLASTIC LEUKEMIA
Primary Investigator: Pacenta, Holly
IRB ID: 2023-062 (OPEN)
Activa® Dystonia Therapy
Primary Investigator: Marks MD, Warren
IRB ID: 593 (OPEN)
ALTE2131 Triptorelin and Protection of Ovarian Reserve in Adolescents and Young Adults with Cancer An NCORP Phase 3 Study
Primary Investigator: Albritton MD, Karen
IRB ID: 2025-025 (OPEN)
ALTE22C1: Chronic Health Conditions in Down Syndrome-Associated Acute Leukemia: The Down Syndrome Phenotyping Acute Leukemia Study in Survivors (DS-PALS Survivors)
Primary Investigator: Beam MD, Donald
IRB ID: 2024-009 (OPEN)
AML23: A phase 2 Study of Venetoclax in Combination with Conventional Chemotherapy in Pediatric Patients with Acute Myeloid Leukemia
Primary Investigator: Heym MD, Kenneth
IRB ID: 2024-032 (OPEN)
An Open-Label, Expanded Access Protocol Using 131-I-Metaiodobenzylguanidine (131 I-MIBG) Therapy in Patients with Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma
Primary Investigator: Granger MD, Meaghan
IRB ID: 2012-026 (OPEN)
An Open-label, Multi-center, Phase IV, Rollover Study for Patients with Sickle Cell Disease who have Completed a prior Novartis-Sponsored Crizanlizumab Study
Primary Investigator: Johnson MD, Clarissa
IRB ID: 2021-060 (OPEN)
An Operationally Seamless, Randomized Phase 2/3 Study Consisting of a Phase 2 Single-Blind, Dose-Evaluation Phase and a Phase 3 Double-Blind, Placebo-controlled Phase to Assess the Efficacy and Safety of Setrusumab in Subjects with Osteogenesis Imperfecta.
Primary Investigator: Steelman MD, Joel
IRB ID: 2023-061 (OPEN)
APAl2020SC
Primary Investigator: Vallance MD, Kelly
IRB ID: 2024-008 (OPEN)
ARAR2221 A Phase 2 Study Using Chemoimmunotherapy with Gemcitanine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinona (NPC) was activated today through COG
Primary Investigator: Greer MD, Chelsee
IRB ID: 2024-071 (OPEN)
Assessment of Clonal Hematopoiesis and its Relationship to Cardiovascular Disease in Hodgkin Lymphoma Survivors. A COG Groupwide Observational Study.
Primary Investigator: Beam MD, Donald
IRB ID: 2023-067 (OPEN)
BioMarin Pharmaceutical Clinical Studies in Children with Idiopathic Short Stature
Primary Investigator: Steelman MD, Joel
IRB ID: 2024-115 (TEMPORARILY CLOSED TO ACCRUAL)
BN44620 - A PHASE IV OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS AND SAFETY OF RISDIPLAM ADMINISTERED AS AN EARLY INTERVENTION IN PEDIATRIC PATIENTS WITH SPINAL MUSCULAR ATROPHY AFTER GENE THERAPY
Primary Investigator: Acord, Stephanie
IRB ID: 2023-078 (OPEN)
Brain functional reorganization as a result of deep-brain stimulation therapy in children with dystonia
Primary Investigator: Papadelis, PhD, Christos
IRB ID: 2021-009 (OPEN)
CAMPFIRE: Children’s and Young Adult Master Protocol for Innovative Pediatric Research
Primary Investigator: Vallance MD, Kelly
IRB ID: 2020-066 (OPEN)
CHAT: A Multi-Institutional Children’s Hospital-Acquired Thrombosis Registry
Primary Investigator: Torres MD, Marcela
IRB ID: 2022-077 (OPEN)
Children’s Mercy Kansas City Cardiac High Acuity Monitoring Program (CHAMP).
Primary Investigator: Roten, Lisa
IRB ID: 2017-033 (OPEN)
Clinical Assessment of Flow in Tetralogy of Fallot by Time-Resolved Volumetric Phase Contrast MRI
Primary Investigator: Muyskens MD, Steve
IRB ID: 2015-047 (OPEN)
Clinical Characteristics and Outcomes of Community-Acquired Pneumonia Requiring Hospitalization among Non-Lung Pediatric Solid Organ Transplant Recipients
Primary Investigator: Rister, Nicholas
IRB ID: 2025-138 (OPEN)
CliniMACS® CD34+ T-cell Depletion of a Haploidentical Stem Cell Product as Part of a Treatment Protocol for Patients with Bone Marrow Failure
Primary Investigator: Howrey MD, Richard P.
IRB ID: 2018-041 (OPEN)
COG_AHOD2131_Albritton
Primary Investigator: Albritton MD, Karen
IRB ID: 2023-056 (OPEN)
Cognitive and Neuroimaging Biosignatures of Well-being in Youth with and without Seizures
Primary Investigator: Cooper, Crystal
IRB ID: 2020-104 (OPEN)
Combined Abnormal General Movement Assessment and High-Resolution Brain Magnetic Resonance Imaging as a Predictor of a Diagnosis of Cerebral Palsy among Patients withHypoxic-Ischemic Encephalopathy
Primary Investigator: Johnson MD, Yvette
IRB ID: CCMC_MRI and GMA_Johnson (OPEN)
Comprehensive Profiling of Neurological Disorders of Somatic Etiology Accelerator Protocol
Primary Investigator: Perry MD, M. Scott
IRB ID: 2024-046 (OPEN)
Congenital Adrenal Hyperplasia Registry for Research and Quality Data Collection
Primary Investigator: Thornton MD, Paul Stephen
IRB ID: CCHCS_CAH Registry_Thornton (OPEN)
Cook Children’s Health Care System Stroke and Thrombosis Registry
Primary Investigator: Torres MD, Marcela
IRB ID: 2020-037 (OPEN)
COPPER HISTIDINATE TREATMENT FOR MENKES DISEASE
Primary Investigator: Stigall, William
IRB ID: 2024-088 (OPEN)
Correlation of non-invasive diastolic parameters with invasive filling pressures in single ventricle patients
Primary Investigator: Loar, Robert
IRB ID: 2020-103 (OPEN)
Cortisol Production in Children and Adolescents with Prader-Willi Syndrome
Primary Investigator: Roy, Sani
IRB ID: 2024-002 (OPEN)
Cystic Fibrosis Patient Registry
Primary Investigator: Schultz MD, Karen D
IRB ID: 394 (OPEN)
descriptive study on infants with confirmed or suspected meningoencephalitis due to parechovirus (PeV) infection
Primary Investigator: Whitworth MD, M. Suzanne
IRB ID: 2023-007 (OPEN)
Electrophysiological Biomarkers of GABA Metabolism in Children with Genetic Epilepsy Syndromes
Primary Investigator: Papadelis, PhD, Christos
IRB ID: 2022-055 (OPEN)
Electrophysiological Biomarkers of GABA metabolism in children with SCN1A+ Dravet Syndrome
Primary Investigator: Papadelis, PhD, Christos
IRB ID: 2022-051 (OPEN)
Epilepsy Genetics Database
Primary Investigator: Keator MD, Cynthia
IRB ID: 2023-074 (OPEN)
Evaluation of the outcome of surgical intervention on the upper extremity in young patients with hemiplegia
Primary Investigator: Marshall MD, James
IRB ID: 2020-098 (OPEN)
Expanded Access Program for Tiratricol in Patients with Monocarboxylate Transporter 8 Deficiency also known as Allan-Herndon-Dudley syndrome (AHDS)
Primary Investigator: Thornton MD, Paul Stephen
IRB ID: 2023-070 (OPEN)
Exploration of Perceived Stress, Sleep, Fatigue, and Biomarkers in Childhood Brain Tumor Survivors
Primary Investigator: Bashore NP, Lisa M
IRB ID: 2018-010 (OPEN)
Fort Worth AYA Oncology Coalition Registry Database
Primary Investigator: Albritton MD, Karen
IRB ID: 2019-017 (OPEN)
Functional Characterization of Children with Chronic Thromboembolic Disease
Primary Investigator: Torres MD, Marcela
IRB ID: 2021-065 (OPEN)
Gastroschisis Outcomes of Delivery Bank
Primary Investigator: Riley MD, David
IRB ID: 2024-066 (OPEN)
Gastroschisis Outcomes of Delivery Study
Primary Investigator: Riley MD, David
IRB ID: 2023-004 (OPEN)
Genzyme Rare Diseases Registry
Primary Investigator: Gillespie MD, Robert
IRB ID: 2009-043 (OPEN)
Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy
Primary Investigator: Beam MD, Donald
IRB ID: 2014-023 (OPEN)
Hyperinsulinism Center Registry for Research and Quality Data Collection
Primary Investigator: Thornton MD, Paul Stephen
IRB ID: 2011-183 (OPEN)
Ictal and Interictal High-Frequency Electrophysiological Activity for the Localization of the Epileptogenic Zone in Children with Refractory Epilepsy
Primary Investigator: Papadelis, PhD, Christos
IRB ID: 2019-070 (OPEN)
Identification of and Genomic Editing of Novel Gene Mutations in Congenital Hyperinsulinism
Primary Investigator: Thornton MD, Paul Stephen
IRB ID: 2023-059 (OPEN)
Improve Care Now
Primary Investigator: Ogunmola MD, Nick
IRB ID: 2021-066 (OPEN)
Improving Diagnosis and Treatment in CPVT
Primary Investigator: Barker, Gregory
IRB ID: 2022-002 (OPEN)
Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma
Primary Investigator: Granger MD, Meaghan
IRB ID: 2018-048 (TEMPORARILY CLOSED TO ACCRUAL)
Kaposiform Hemangioendothelioma: Hematology and Oncology Survey (KHHAOS) Study
Primary Investigator: Heym MD, Kenneth
IRB ID: 2021-051 (OPEN)
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
Primary Investigator: Beam MD, Donald
IRB ID: 2010-109 (OPEN)
Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or large B-cell lymphoma patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release
Primary Investigator: Pacenta, Holly
IRB ID: 2020-101 (OPEN)
Multi-center Evaluation of the Threat of Established and Emerging Respiratory Viral Infections in Pediatric Transplant Recipients
Primary Investigator: Whitworth MD, M. Suzanne
IRB ID: 2022-080 (OPEN)
Multi-modal neuroimaging in children with cerebral palsy to assess functional and anatomical reorganization in relation to sensory and motor functions
Primary Investigator: Papadelis, PhD, Christos
IRB ID: 2019-068 (OPEN)
n/a
Primary Investigator: Vallance MD, Kelly
IRB ID: 2025-046 (OPEN)
N/A
Primary Investigator: Tran, Lihn
IRB ID: 2024-111 (OPEN)
NANT 2021-01: PHASE II STUDY OF EX-VIVO EXPANDED ALLOGENEIC UNIVERSAL DONOR TGF?i NK CELL INFUSIONS IN COMBINATION WITH TEMOZOLOMIDE, IRINOTECAN, DINUTUXIMAB, AND SARGRAMOSTIM IN PATIENTS WITH RELAPSED OR REFRACTORY NEUROBLASTOMA: The STING (Sequential Temozolomide, Irinotecan, NK cells and GD2 mAb) Trial
Primary Investigator: Greer MD, Chelsee
IRB ID: 2024-080 (OPEN)
National Pediatric Cardiology Quality Improvement Collaborative (NPC-QIC) - A Collaborative Initiative to Improve Care of Children with Complex Congenital Heart Disease
Primary Investigator: Roten, Lisa
IRB ID: 2017-032 (OPEN)
National Registry of Pediatric Cancer Patients Diagnosed with COVID-19
Primary Investigator:
IRB ID: 2020-034 (OPEN)
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol (APEC1621SC)
Primary Investigator: Vallance MD, Kelly
IRB ID: 2017-065 (OPEN)
Neutrophil Gelatinase-Associated Lipocalin (NGAL) and serum Cystatin C levels in children after Cardiopulmonary Bypass (CPB)
Primary Investigator: Marshall MD, James
IRB ID: 2020-041 (OPEN)
NPS and/or NS samples in M4RT and Bojana
Primary Investigator: Pence, Morgan
IRB ID: 2024-102 (OPEN)
Observational study of pediatric thrombotic disease: the Throm-PED registry
Primary Investigator: Torres MD, Marcela
IRB ID: 2021-085 (OPEN)
Open-label study investigating efficacy, safety and pharmacokinetics of concizumab prophylaxis in children below 12 years with haemophilia A or B with or without inhibitors.
Primary Investigator: McCavit MD, Timothy
IRB ID: 2024-012 (OPEN)
Paroxysmal Nocturnal Hemoglobinuria / IPIG registry study/USA
Primary Investigator: Beam MD, Donald
IRB ID: 2022-093 (OPEN)
Pediatric International DBS (PEDiDBS) Registry
Primary Investigator: Marks MD, Warren
IRB ID: 2016-013 (OPEN)
PEPN22P1: A Pharmacokinetic Study of VinCRIStine in Infants Dosed According to BSA-Banded Infant Dosing Tables and Older Children Dosed by Traditional BSA Methods
Primary Investigator: Pacenta, Holly
IRB ID: 2022-112 (OPEN)
Phase 1/2 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited CD34+ Human Hematopoietic Stem and Progenitor Cells (EDIT-301) in Subjects with Severe Sickle Cell Disease
Primary Investigator: Eames MD, Gretchen
IRB ID: 2022-023 (OPEN)
Phase 3 trial for patients with Dyskinetic Cerebral Palsy
Primary Investigator: Marks MD, Warren
IRB ID: 2022-027 (OPEN)
Predicting ECMO NeuroLogICal Injuries using mAchiNe Learning (PELICAN)
Primary Investigator: Nkwantibisa, Raymond
IRB ID: 2023-075 (OPEN)
Presurgical Mapping of the Eloquent Cortex in Children with Drug Resistant Epilepsy Using Videogames
Primary Investigator: Papadelis, PhD, Christos
IRB ID: 2024-028 (OPEN)
Project DANCES (Diversity in Aya caNCEr Survivors)
Primary Investigator:
IRB ID: 2024-048 (OPEN)
Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
Primary Investigator: Eames MD, Gretchen
IRB ID: 2019-061 (OPEN)
Protocol for a Research Sample Repository for Hematopoietic Cell Tranplantation, Other Cellular Therapies, and Marrow Toxic Injuries
Primary Investigator: Eames MD, Gretchen
IRB ID: 2019-062 (OPEN)
PRWCC_Foresight_Pacenta
Primary Investigator: Pacenta, Holly
IRB ID: 2024-059 (OPEN)
Quantitative Assessment of Sucking for Early Diagnosis of Brain Injury in Infants at High Risk
Primary Investigator: Papadelis, PhD, Christos
IRB ID: 2019-085 (OPEN)
Randomization of Cytarabine Monotherapy versus Standard-of-Care Vinblastine/Prednisone for Frontline Treatment of Langerhans Cell Histiocytosis
Primary Investigator: Ray MD, Anish
IRB ID: 2019-067 (OPEN)
RBDD-PLG Project; International Retrospective and Prospective Study of Individuals affected with Hypoplasminogenemia
Primary Investigator: Torres MD, Marcela
IRB ID: 2019-028 (OPEN)
RCT for Intestinal Failure.
Primary Investigator: Osuntokun MD, Bankole Oluseyi
IRB ID: 2024-035 (OPEN)
Reducing Ethnic Disparities in Acute Leukemia (REDIAL) Consortium Retrospective Chart Review
Primary Investigator: Heym MD, Kenneth
IRB ID: 2019-051 (OPEN)
Retrospective data analysis of neurophysiological data for intraoperative or epilepsy monitoring
Primary Investigator: Papadelis, PhD, Christos
IRB ID: 2022-059 (OPEN)
Robot-assisted hand training to induce manual functional change and cerebral neural plasticity in children with cerebral palsy
Primary Investigator: Papadelis, PhD, Christos
IRB ID: 2021-012 (OPEN)
Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Infants and Children with SCN1A-positive Dravet Syndrome.
Primary Investigator: Perry MD, M. Scott
IRB ID: 2022-076 (OPEN)
Seizures and Children's Outcomes after Stroke
Primary Investigator: Herring, Rachelle
IRB ID: 2022-067 (OPEN)
Sensory and Affective Processing in Children with Autism Spectrum Disorder
Primary Investigator: Papadelis, PhD, Christos
IRB ID: 2024-047 (OPEN)
Signatera Efficacy Study
Primary Investigator:
IRB ID: Dell Childrens_Signatera Efficacy_Ray (OPEN)
SJiMB21: Phase 2 Study of Molecular and Clinical Risk-Directed Therapy for Infants and Young Children with Newly Diagnosed Medulloblastoma
Primary Investigator: Zhao, MD, Sibo
IRB ID: 2023-057 (OPEN)
Standardizing Treatments for Pulmonary Exacerbations: A platform for evaluating treatment decisions to improve outcomes (STOP360-IP-22)
Primary Investigator: Schultz MD, Karen D
IRB ID: 2022-091 (OPEN)
STK-001-DS-301_Stoke_Dravet Syndrome
Primary Investigator: Perry MD, M. Scott
IRB ID: Stoke_STK-001-DS-301_Perry (OPEN)
Stroke Study
Primary Investigator: Torres MD, Marcela
IRB ID: 2023-029 (OPEN)
Survey of the National Lipid Association’s Membership - Opinions of the 2011 National Heart, Lung and Blood Institute’s Expert Panel Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents.
Primary Investigator: Wilson MD, Don
IRB ID: 2013-028 (OPEN)
Targeted approach to Langerhans Cell Histiocytosis (LCH) using MEK inhibitor, Trametinib.
Primary Investigator: Ray MD, Anish
IRB ID: 2023-058 (OPEN)
Test protocol
Primary Investigator:
IRB ID: CCHCS_Test_PI (OPEN)
Testicular tissue cryopreservation for fertility preservation in patients facing infertility-causing diseases or treatment regimens
Primary Investigator: Palmer, MD, Blake
IRB ID: 2020-053 (OPEN)
The American Thrombosis and Hemostasis Network (ATHN) National Web Tracker
Primary Investigator: Sanders MD, Joann
IRB ID: 2011-160 (OPEN)
The Impact of Massage Therapy on Post-Surgical Pain, Anxiety, Quality of Life, and Opioid Analgesia Exposure on Children After Thoracic or Lumbar Surgery.
Primary Investigator:
IRB ID: 2020-088 (OPEN)
Tissue Banking- Collecting and Banking Human Tissue Samples for Future Use
Primary Investigator: Zhao, MD, Sibo
IRB ID: 2020-093 (OPEN)
Towards the Establishment of Standards of Practice and the Inititation of Multi-Center, Multi-National Clinical Trials for Neonates and Children with Stroke
Primary Investigator: Torres MD, Marcela
IRB ID: 2012-008 (OPEN)
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Primary Investigator: Vallance MD, Kelly
IRB ID: 2020-097 (OPEN)
Unknown
Primary Investigator: Whitworth MD, M. Suzanne
IRB ID: Childrens National_RWE Maribavir_Whitworth (OPEN)
Utility of RESPONDR® TNF, a laboratory developed diagnostic test, in a real-world inflammatory bowel disease population
Primary Investigator: Huang, MD, Clifton
IRB ID: Prometheus Laboratories_RESPONDR 24IBD02_Huang (OPEN)
UTSW_ASH RESEARCH_Johnson
Primary Investigator: Johnson MD, Clarissa
IRB ID: 2022-116 (OPEN)
Venetoclax EAP IND 152442
Primary Investigator: Heym MD, Kenneth
IRB ID: 2020-080 (OPEN)
Donec tincidunt auctor bibendum. Phasellus laoreet diam at erat blandit, non consequat enim commodo.
Nam vel ante facilisis, commodo eros nec, fermentum tortor. Suspendisse sit amet sem non leo volutpat elementum.
Nulla rhoncus eros id tellus luctus, nec commodo tortor semper. Vivamus eget turpis vitae mi varius interdum.
Quisque convallis lacus ac tellus egestas, et auctor enim aliquam.
Curabitur eu dui ut diam luctus sollicitudin at sed lorem. Aliquam pharetra felis eget lacus egestas, non elementum risus consequat.
